Graphene Development Service
To help our customers achieve more effective and safe gene therapy, our company is working on the development of a variety of non-viral vectors, including graphene-based gene delivery systems. We focus on various types of modification and functionalization of graphene to develop graphene-based nanocarriers suitable for nucleotide loading and delivery for research applications in rare diseases.
Background
In recent years, the combination of nanotechnology concepts and non-viral gene therapy approaches has provided a breakthrough in biomedicine. Nanotechnology offers important improvements in gene vector design to obtain ideal vectors. The application of graphene and its derivatives, which are sheet-like carbon nanomaterials, has been extended to gene delivery as nanocarriers due to their unique structure and chemical properties that provide a high capacity for gene loading.
Several reports have demonstrated the great interest graphene-based nanoplatforms have attracted in the delivery of various therapeutic agents such as drugs and genes, and are considered to be effective cargo delivery systems for cancer therapy. In the last decade, graphene-based carriers have been used successfully in in vitro and in vivo gene therapy applications. Therefore, the development of safe and efficient graphene-based gene carriers with the aid of nanotechnology is expected to provide new avenues for gene therapy of rare diseases.
Fig. 1 Schematic illustration of graphene-based nanocarriers for gene delivery applications. (Imani R, et al., 2018)
Our Services
We provide comprehensive and specialist scientific services to help our customers design and develop graphene-based nanocarriers for gene therapy of rare diseases. Our researchers have established multiple protocols involving the modification of the surface of graphene and its derivatives with various polymers or ligands to improve biostability, biocompatibility, cellular uptake, and increase in gene loading capacity. We offer a variety of services designed to help our customers solve the challenging problems of graphene-based gene therapy.
- Design of graphene-based nano-carrier for efficient gene delivery
We help customers design effective graphene-based nano-carrier systems for the delivery of various types of therapeutic nucleotides, including plasmid DNA (pDNA), antisense oligonucleotides (AONs), small interfering RNA (siRNA), short hairpin RNA (shRNA), and MicroRNA (miRNA). We comprehensively considered several physicochemical parameters such as surface charge, size, shape, and surface chemistry to design nano-carriers and change the fate of nano-carriers inside the body by manipulating these factors. - Functionalization of graphene used in the delivery
We have made graphene suitable for intracellular gene delivery applications through two main approaches, including covalent and non-covalent modification with different modifiers to provide DNA/RNA condensation. We provide modification of graphene derivatives by various modifiers, including polyethylenimine (PEI), polyethylene glycol (PEG), dendrimers, poly-L-lysine (PLL), chitosan, poly(sodium 4-styrenesulfonates) (PSS), poly(2-dimethyl aminoethyl methacrylate) (PDMAEMA), and peptides. - Development of dual gene/drug delivery systems by graphene-based nano-carriers
The co-delivery of drugs and nucleotide-based therapeutics by graphene-based nano-carriers has been proved to have wide prospects for the therapeutics of the target diseases, particularly cancer. We help customers develop graphene-based dual gene/drug delivery systems, such as the PEG/PEI/CS-Aco complex for the delivery of doxorubicin (DOX) and shRNA to the human hepatic cell line. - Optimization of delivery efficacy
We provide various optimization strategies for improving delivery efficacy. We provide a variety of target agents to improve graphene-based nanocarriers, including:- Ligands, such as folate acid and hyaluronic acid.
- Proteins, such as transferrin (TF) or lactoferrin (LF).
- Peptide and aptamer, such as cell-penetrating peptides (CPPs), cell-targeting peptides (CTPs), and AS1411 aptamer.
Our company has the strength to provide customers with graphene-based nano-carrier development services to accelerate gene therapy for rare diseases. If you are interested in our services, please contact us for more details.
Reference
- Imani, R.; et al. Graphene-based nano-carrier modifications for gene delivery applications. Carbon, 2018, 140: 569-591.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
